Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prost...(limited therapeutic choices. The...)

The picoplatin data will be presented in a poster session on Friday, February 27, at 11:45 a.m. Eastern Time (abstract #186/poster #A38) during the American Society of Clinical Oncology's (ASCO) 2009 Genitourinary Cancers Symposium in Orlando, Fla. Picoplatin, the Company's lead product candidate, is a new generation platinum-based chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations for the treatment of solid tumors.

Phase 2 CRPC Trial Design and Results to Date

Patient enrollment in the ongoing Phase 2 trial of picoplatin in patients with metastatic CRPC was completed in December 2007. The trial enrolled 30 patients with metastatic CRPC who had not received prior chemotherapy. The objective of the study is to evaluate the efficacy and safety of intravenous picoplatin (120 mg/m squared) administered every three weeks in combination with full doses of docetaxel (75 mg/m squared) with daily prednisone (5 mg) as a first-line treatment. PSA response (defined as a PSA reduction of at least 50 percent from baseline maintained for at least four weeks) is the primary endpoint; secondary endpoints include safety, radiologic response, time to progression and overall survival.

The latest trial findings, scheduled for presentation at the ASCO 2009 GU Symposium, demonstrated that:

• Reductions of PSA levels of at least 50 percent were achieved in 21 of 27 (78 percent) evaluable patients who received picoplatin in combination with docetaxel and prednisone. In contrast, data from published literature report PSA responses of approximately 45 percent in patients who received docetaxel/prednisone.
• To date, the median time to PSA progression is 8.5 months with picoplatin in combination with docetaxel and prednisone.
• Radiologic response
  '/>"/>